BL
PMCB icon

BFSG LLC’s PharmaCyte Biotech PMCB Stock Holding History

BFSG LLC’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4 Hold
5
– – ﹤0.01% 767
2026
Q1 		$4 Hold
5
– – ﹤0.01% 749
2025
Q4 		$4 Hold
5
– – ﹤0.01% 718
2025
Q3 		$5 Hold
5
– – ﹤0.01% 704
2025
Q2 		$6 Hold
5
– – ﹤0.01% 671
2025
Q1 		$7 Hold
5
– – ﹤0.01% 673
2024
Q4 		$8 Hold
5
– – ﹤0.01% 671
2024
Q3 		$10 Hold
5
– – ﹤0.01% 639
2024
Q2 		$10 Sell
5
-2
-29% -$4 ﹤0.01% 617
2024
Q1 		$17 Buy
+7
New +$15 ﹤0.01% 658

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

BFSG LLC's PMCB Position: Q2 2026 in Review

BFSG LLC held its PharmaCyte Biotech (PMCB) position steady in Q2 2026 at 5 shares worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #767.

BFSG LLC first reported a position in PMCB in Q1 2024 and has held it in 10 quarters since. The position peaked at $17 in Q1 2024. 19 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • BFSG LLC held 5 shares of PharmaCyte Biotech worth $4 as of Q2 2026.
  • BFSG LLC left its PharmaCyte Biotech share count unchanged in Q2 2026.
  • PharmaCyte Biotech made up ﹤0.01% of BFSG LLC's portfolio in Q2 2026, its #767 holding.
  • BFSG LLC first reported a position in PharmaCyte Biotech in Q1 2024 and has held it in 10 quarters since.
  • BFSG LLC's PharmaCyte Biotech position peaked at $17 in Q1 2024.
  • 19 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on BFSG LLC's 13F filing for Q2 2026, filed 20 Jul 2026.